Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Net Income (2016 - 2025)

Traws Pharma (TRAW) has disclosed Net Income for 14 consecutive years, with -$4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income rose 52.5% to -$4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$9.3 million, a 93.41% increase, with the full-year FY2024 number at -$142.4 million, down 601.42% from a year prior.
  • Net Income was -$4.1 million for Q3 2025 at Traws Pharma, up from -$5.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$3.8 million in Q4 2021 to a low of -$123.3 million in Q2 2024.
  • A 5-year average of -$11.9 million and a median of -$4.6 million in 2021 define the central range for Net Income.
  • Peak YoY movement for Net Income: crashed 2575.66% in 2024, then skyrocketed 52.5% in 2025.
  • Traws Pharma's Net Income stood at -$3.8 million in 2021, then crashed by 52.38% to -$5.7 million in 2022, then increased by 22.18% to -$4.5 million in 2023, then decreased by 18.29% to -$5.3 million in 2024, then rose by 23.17% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Net Income are -$4.1 million (Q3 2025), -$5.3 million (Q4 2024), and -$8.5 million (Q3 2024).